Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting-Reference-Cited by-同舟云学术

Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting

Published:2019-07 Issue: Volume:115 Page:4-12
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Depenni Roberta,Cossu Rocca Maria,Ferrari Daris,Azzarello Giuseppe,Baldessari Cinzia,Alù Massimiliano,Nolé Franco,Codecà Carla,Boscolo Giorgia,Piccininni Marco,Cavalieri Stefano^ORCID,Bossi Paolo

Funder

Merck KGaA

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Head and neck cancer;Argiris;Lancet,2008

2. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck;Jacobs;J Clin Oncol,1992

3. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck;Forastiere;J Clin Oncol,1992

4. Platinum based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

5. Cetuximab relative dose intensity (RDI) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first observational prospective study in unselected patients (DIRECT trial);Guigay;Ann Oncol,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305;European Journal of Cancer;2024-03

2. Early recurrence, time‐to‐recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M‐HNSCC) patients treated with first line platinum‐based chemotherapy;Cancer Medicine;2024-02

3. Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma;American Journal of Otolaryngology;2024-01

4. The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma;Journal of Cancer;2024

5. Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent/metastatic nasopharyngeal carcinoma: A meta‑analysis and systemic review;Oncology Letters;2023-04-05